{
    "Trade/Device Name(s)": [
        "SPOTCHECK\u00ae Blood Spot Control",
        "Astoria-Pacific SPOTCHECK\u00ae Blood Spot Controls"
    ],
    "Submitter Information": "Astoria-Pacific, Inc.",
    "510(k) Number": "K090940",
    "Predicate Device Reference 510(k) Number(s)": [
        "K990827"
    ],
    "Regulatory Class": "Class I",
    "Product Code(s)": [
        "JJT"
    ],
    "Summary Letter Date": "December 14, 2009",
    "Summary Letter Received Date": "October 21, 2009",
    "Submission Date": "October 19, 2009",
    "Regulation Number(s)": [
        "21 CFR 862.1660"
    ],
    "Regulation Name(s)": [
        "Quality control material (assayed and unassayed)"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Galactose-1-phosphate Uridyltransferase (GALT)",
        "Biotinidase"
    ],
    "Specimen Type(s)": [
        "Blood spot (mixture of human serum and human red blood cells)"
    ],
    "Specimen Container(s)": [
        "Whatman 903A filter paper"
    ],
    "Instrument(s)/Platform(s)": [
        "SPOTCHECK system"
    ],
    "Method(s)/Technology(ies)": [
        "Enzyme activity assay"
    ],
    "Methodologies": [],
    "Submission Type(s)": [
        "Control"
    ],
    "Document Summary": "FDA 510(k) summary for Astoria-Pacific SPOTCHECK Blood Spot Controls used as quality controls in newborn screening enzyme activity assays for GALT and Biotinidase",
    "Indications for Use Summary": "Used for monitoring assay performance during in vitro diagnostic newborn screening for deficient Galactose-1-phosphate Uridyltransferase (GALT) and/or Biotinidase enzyme activity",
    "fda_folder": "Clinical Chemistry"
}